-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 8, Shanghai Pharmaceuticals issued an announcement stating that the rivaroxaban tablets of its subsidiary, Changzhou Pharmaceutical Factory, received the "Drug Registration Certificate" issued by the State Drug Administration, and the drug was approved for production
Rivaroxaban is a new type of oral anticoagulant.
Clinically, Rivaroxaban is widely used in the prevention and treatment of venous thromboembolic diseases and stroke prevention in non-valvular atrial fibrillation.
As of the date of this announcement, the main manufacturers of the drug in China include Qilu Pharmaceutical Co.
The IQVIA database shows that the purchase amount of the drug hospital in 2020 will be RMB 2.